A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years
Conditions: HPV InfectioN; HPV-Related Carcinoma Interventions: Biological: 11-valent recombinant human papilloma virus vaccine (Hansenula polymorpha); Biological: placebo Sponsors: National Vaccine and Serum Institute, China; Chengdu Institute of Biological Products Co.,Ltd.; Simoon Record Pharma Information Consulting Co., Ltd.; Beijing Kantorico Statistical Technology Co., Ltd.; Guangxi Center for Disease Control and Prevention; Hunan Cent er for Disease Control and Prevention; Sichuan Center for Disease Control and Prevention; Shanxi Center for Disea...
Source: ClinicalTrials.gov - March 2, 2022 Category: Research Source Type: clinical trials
Intralesional HPV Vaccine for Condylomata
Conditions: Human Papilloma Virus; Warts; Warts, Genital; Condyloma; Condylomata Acuminata Intervention: Biological: nonavalent human papillomavirus vaccine Sponsor: University of California, San Francisco Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 21, 2021 Category: Research Source Type: clinical trials
